Essential Update 2023/2024: Multidisciplinary Treatment for Invasive Intraductal Papillary Mucinous Carcinoma
Author:
Open Access
- 21 April 2025
- journal article
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 9 (4) , 643-649
Abstract
Invasive intraductal papillary mucinous carcinoma (IPMC) has a high malignant potential, with surgical resection being the only potentially curative treatment. However, even after surgical resection, recurrence occurs frequently and the prognosis is poor once recurrence develops. While retrospective studies aiming to achieve long‐term survival in invasive IPMC patients have been reported, the rarity of invasive IPMC has resulted in small‐scale datasets, leading to low levels of evidence. Consequently, the utility of adjuvant therapy after surgery, neoadjuvant therapy (NAT) before surgery, and treatments for postoperative recurrence in invasive IPMC remains unclear, with treatment strategies varying by institution—ranging from surgical resection alone to approaches based on conventional pancreatic cancer treatment. Recently, several large‐scale multicenter studies on invasive IPMC have been reported. These studies suggested that while adjuvant therapy after surgery may not be beneficial for all invasive IPMC patients, it could potentially extend survival in cases with advanced‐stage disease. Regarding NAT before surgery for invasive IPMC, the number of reported cases is extremely limited, and no definitive evidence has been established. For postoperative recurrence of invasive IPMC, some studies have indicated that administering treatment may prolong survival. Although these large‐scale studies have gradually clarified certain characteristics of invasive IPMC, they are all retrospective in nature, resulting in a low level of evidence. To achieve long‐term survival for invasive IPMC patients, large‐scale prospective multicenter studies are needed in the future.Keywords
This publication has 40 references indexed in Scilit:
- Is multidisciplinary treatment effective for invasive intraductal papillary mucinous carcinoma?Annals of Gastroenterological Surgery, 2024
- Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)—a randomized phase II trial of the AIO pancreatic cancer groupAnnals of Oncology, 2022
- IPMN-associated pancreatic cancer: Survival, prognostic staging and impact of adjuvant chemotherapyEuropean Journal of Surgical Oncology, 2022
- Determining the role of adjuvant therapy in Invasive Intraductal Papillary Mucinous Neoplasms; a systematic review and meta-analysisEuropean Journal of Surgical Oncology, 2022
- Adjuvant Chemotherapy in the Treatment of Intraductal Papillary Mucinous Neoplasms of the Pancreas: Systematic Review and Meta‐AnalysisWorld Journal of Surgery, 2021
- Recurrence patterns after surgical resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas; a multicenter, retrospective study of 1074 IPMN patients by the Japan Pancreas SocietyJournal of Gastroenterology, 2019
- Factors Associated With Invasive Intraductal Papillary Mucinous Carcinoma of the PancreasJAMA Surgery, 2017
- The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN)Cancer, 2015
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic CancerJAMA, 2013
- Treatment Strategy for Intraductal Papillary Mucinous Neoplasm of the Pancreas Based on Malignant Predictive FactorsArchives of Surgery, 2009